Symbols

RGNX

Regenxbio·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 1

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About RGNX

Regenxbio Inc.

A biotechnology company that develops gene therapies for treating rare genetic diseases

Industry

Biological Technology

Established Date

07/16/2008

Listing Date

09/17/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

371

Fiscal Year Ends

12-31

Website

www.regenxbio.com

Security Type

Common stock

Office address

9804 Medical Center Drive Rockville MD 20850

Business

Introduction

Regenxbio Inc., was founded on July 16, 2008. The company is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus gene therapies. In AAV gene therapy, viral genes are removed from AAV (a small, non-pathogenic cold virus) to build a biological delivery tool called a vector. The therapeutic gene sequence is then inserted into it to form a recombinant vector. The company has a proprietary AAV gene delivery platform that contains exclusive rights to over 100 new AAV vectors, including AAV7, AAV8, AAV9 and AAVrh 10. The company's mission is to develop and commercialize gene therapy products that are injected directly into the body (i.e., administered in vivo) based on its NAV technology platform, thereby improving the lives of patients with serious diseases and significant unmet medical needs.

Company Financials

EPS

RGNX has released its 2025 Q4 earnings. EPS was reported at -1.3, versus the expected -0.72, missing expectations. The chart below visualizes how RGNX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

RGNX has released its 2025 Q4 earnings report, with revenue of 30.34M, reflecting a YoY change of 43.00%, and net profit of -67.15M, showing a YoY change of -31.19%. The Sankey diagram below clearly presents RGNX's revenue sources and cost distribution.